NICE has recommended two new treatment options for some people who have conditions that put them at extremely high risk of heart attacks or strokes.
The draft guidance recommends alirocumab (Praluent, Sanofi) and evolocumab (Repatha, Amgen) for adults with primary hypercholesterolaemia or mixed dyslipidaemia to help reduce their risk of cardiovascular disease. The drugs are recommended for people with these conditions whose cholesterol levels are not controlled adequately using other drugs such as statins, or who can’t tolerate statins because of their side effects.
